Based on computer-assisted drug design, a series of novel pyrimidine derivatives was successfully synthesized and characterized by 1 H NMR, 13 C HNMR, and MS spectra. All the new compounds were evaluated for their activity against focal adhesion kinase and showed low IC 50 values in comparison with control drugs. In particular, for compound 8i, its IC 50 value was 0.060 mM, suggesting its advantage as a focal adhesion kinase inhibitor. To evaluate the potentiality of these compounds as PET imaging agents in cancer detection, compounds 8a, 8c, 8h, and 8i were successively labeled with 18 F. The four 18 Flabeled pyrimidine derivatives showed appropriate log P values and high stability in physiological saline and mouse plasma. Noticeably, compound [ 18 F]-8a with a 4-methoxyl group at the benzene ring exhibited good in vivo biodistribution data in mice bearing the S180 tumor, which promoted a further microPET imaging study of compound [ 18 F]-8a. The microPET image of [ 18 F-8a] administered into the S180 tumor-bearing mice acquired at 60 min post-injection illustrated that the uptake in S180 tumor was obvious. These results suggested that compound [ 18 F]-8a might be a new probe for PET tumor imaging.
Introduction
Cancer is now not only the leading cause of death, but also a major public health problem all around the world. 1 The increasing growth and aging of the population are the main factors for the occurrence of cancer, 2 while in developed countries, it may be induced by a plethora of both external and internal factors. To date, many anticancer drugs have been marketed. The most well-known and widely clinical used type of anticancer agents is nitrogen mustard (nonspecic bifunctional DNA-alkylating agents), which has a serious drawback in that it could cause DNA damage by interrupting DNA biosynthesis. Melphalan, chlorambucil, cyclophosphamide, and bendamustine are revolutionary discoveries in the treatment of cancers. However, many drawbacks exist in these derivatives such as low specicity to tumor cells, eventual loss in activity, high chemical reactivity, and bone-marrow toxicity.
3 Therefore, the development of novel anticancer drugs with high specicity, activity retention, and low chemical reactivity as well as no bonemarrow toxicity is of great emergency.
Focal adhesion kinase (FAK) is a multi-domain non-receptor tyrosine kinase and scaffold protein localized to focal adhesions, 4 which is uniquely positioned at the convergence point of integrins and receptor tyrosine kinase signal transduction pathways, transmitting signals from the extracellular matrix (ECM) to the cell cytoskeleton. A variety of diseases have been identied to be related with FAK, especially cancers, in which FAK is highly expressed or over-expressed at both the transcriptional and translational level. FAK signaling pathways can stimulate tumor progression and metastasis through the regulation of cell migration, invasion, ECM, and angiogenesis.
5-7
Thus, this protein has emerged as a promising therapeutic target, 8 and efforts to investigate FAK for an anticancer effect are under intense investigation. 9 Accordingly, the inhibition against FAK is considered as an effective antineoplastic strategy by inducing apoptosis and sensitizing tumor cells to chemotherapy.
10,11
TAE-226, PF-562271, and PF-573228 are the classical FAK inhibitors. TAE-226 is a novel low-molecular-weight ATPcompetitive tyrosine kinase inhibitor targeting FAK with potent and selective in vitro activity (IC 50 ¼ 5.5 nM). It could inhibit the phosphorylation of FAK, the downstream oncogenic signals, the extracellular signal-related kinase, and the S6 ribosomal protein.
12 TAE-226 shows impressive antitumor activity against various cancers, such as neuroblastoma, 13 breast cancer, 14, 15 and ovarian cancer. 16 However, the development of TAE-226 has been discontinued in the preclinical stage due to its severe effects on glucose metabolism in animal studies and its inhibition of insulin activity (IC 50 ¼ 44 nM).
17 PF-562271, developed by Pzer, is a dual FAK/Pyk2 inhibitor, and is identied as the rst-in-class and rst-in-human FAK inhibitor (FAK IC 50 ¼ 1.5 nM, PYK2 IC 50 ¼ 14 nM) being evaluated in the clinic.
PF-573228 is another novel small molecule FAK inhibitor that interacts with FAK in the ATP-binding pocket and blocks the catalytic activity of recombinant FAK protein or endogenous FAK. The treatment of cells with PF-573228 blocks FAK phosphorylation on Tyr397 and concomitantly reduces the tyrosine phosphorylation of paxillin. PF-573228 provides an appropriate tool to dissect the role of FAK in the regulation of cell adhesion signaling and adhesion dynamics.
18
From the above three FAK inhibitors, it can be seen that the same structural feature is the pyrimidine ring, which attracts our intensive interest in studying pyrimidine derivatives as novel FAK inhibitors related to cancers. As we know, the pyrimidine ring is a cyclic amine with two nitrogen atoms. It is the main component of many heterocyclic compounds and plays important roles in many biological processes, such as the synthesis and function of nucleic acids, several vitamins, coenzymes, and purines, etc. 19, 20 Pyrimidines and their derivatives exhibit a broad spectrum of biological activities including signicant in vitro activity against DNA and RNA, potential inhibition property against polio herpes viruses, and as antitumor, anti-HIV, antimicrobial, insecticidal, and antiviral agents.
21,22
In view of the above observations, a series of novel pyrimidine derivatives as FAK-targeted tumor imaging agents were designed based on the following considerations:
(1) The key framework structure of TAE-226, PF-562271, and PF-573228 should remain as in Fig. 1 to keep the excellent inhibitory activity against FAK. While the strong electronwithdrawing chloro and triuoromethyl groups are changed into a bromo moiety to explore the effects of electron density at the frame structure on the bioactivity.
(2) The literature has reported that the aliphatic chain is usually considered to be a good substituent to regulate the solubility of target compounds. Given this, aliphatic chains at different lengths are introduced into the phenyl ring at the 2-position of pyrimidine ring in order to investigate the physicochemical characters of the designed compounds on the ability against FAK.
(3) To get relatively comprehensive good structure-activity relationships of the target compounds, another phenyl ring is modied by an electron-withdrawing or electron-donating group at different positions, such as methoxyl and carboxyl moieties (Fig. 2) .
To make this design more rational, molecular docking between the title compounds and FAK was carried out rst (see ESI †). The total score of compound 8a was demonstrated to be 6.04, and it could form two hydrogen bonds with the FAK residues GLU430 and CYS502 through the O and N atoms, which motivates our interest in further investigating its potentiality as a small molecular antitumor-agent targeting FAK (Fig. 3) .
The noninvasive imaging of FAK by positron emission tomography (PET) has the ability to not only provide an innovative pharmacological approach for the diagnosis of diseases but can also contribute to a better understanding of the physiological and pathophysiological functions of FAK. 23 
18
F is the most favorable positron emission isotope out of all the commonly used ones, which is mainly due to its longer physical half-life of 110 min, its comparable size to the H atom, and its lower positron energy. 24 However, until now, only a few research studies on 18 F-labeled FAK imaging agents have been reported.
Therefore, there is still a need to develop an 18 F-labeled FAK imaging agent with high effect and low toxicity, and for providing useful diagnostic tools to investigate diseases related to FAK, including cancer.
25
In this paper, all the newly synthesized compounds were evaluated for their in vitro inhibitory activity against FAK, and some target compounds were radiolabeled by 18 F. The radioactive pyrimidine derivatives were further investigated via partition coefficients determination, in vitro stability studies, and in vivo biodistribution studies in S180-bearing mice to better support their potency as PET imaging agents for cancer detection. Importantly, microPET imaging was also studied to develop new F-18 labeled PET imaging agents based on pyrimidine derivatives.
Experimental

General methods
All the chemicals and reagents used in the study were of commercial quality and were used as purchased. Proton nuclear magnetic resonance ( 1 H NMR) spectra were acquired using a BRUKER AVANCE® III HD 400 Spectrometer in CDCl 3 solutions at room temperature. Chemical shis were given in chemical shi (d) as parts per million (ppm) relative to tetramethylsilane (TMS), which was used as an internal standard, and were referenced to the centerline of deuterochloroform Fig. 1 The structures of some classical FAK inhibitors. (7.27 ppm 1 H NMR). The ESI-MS spectra were determined on cartridge, 37-55 mm particle size) with 1 N NaHCO 3 (10 mL), followed by deionized water (10 mL), and the Waters Sep-Pak® C18 Plus Light Cartridges (130 mg sorbent per cartridge, 55-105 mm particle size) with methanol (10 mL) and deionized water (10 mL) before use. Radiopharmaceuticals were puried and their radiochemical purity were determined on a Shimadzu® LC-20AT HPLC apparatus equipped with a SPD-20A UV detector (l ¼ 254 nm) and Bioscan® ow count 3200 NaI/PMT g-radiation scintillation detector. We performed the radiopharmaceutical HPLC separations on an Inertsil® ODS-3 C18 reverse phase semi-preparative column (GL Sciences, Inc. 5 mm, 10 mm Â 250 mm), and we carried out the elution with a binary gradient system at a ow rate of 2.0 mL min À1 . Their radiochemical purity determinations were achieved on a Kromasil® 100-5C18 reverse phase column (AkzoNobel, 5 mm, 4.6 mm Â 250 mm), and elution was carried out with a binary gradient system at a ow rate of 2.0 mL min À1 . S180 ascites sarcoma mice were purchased from Beijing Vitalriver Animal Technology Co., Ltd, and normal ICR mice (20-25 g, female) were provided by Beijing Xinglong Animal Technology Co., Ltd. 18 F radioactivity of the tissues and organs of interest was measured on a PerkinElmer® 2480 WIZARD 2 automatic gamma counter. The microPET imaging was performed on a SuperArgus PET/CT, which was designed and manufactured by SEDECAL (Sociedad Española de Electromedicina y Calidad, S.A.). All the protocols requiring the use of mice were in accordance with the "guidelines for humane treatment of laboratory animals" promulgated by the National Health and Family Planning Commission of China, and were approved by the Animal Care Committee of Beijing Normal University. . Furthermore, the mole of 3 used in the next step of the reaction was also calculated as the hypothetical mass of pure 3 divided by the relative molecular mass of 3.
Synthesis of intermediate 2
Synthesis of intermediate 6a
Here, 4-methoxyphenyl amine (150 mmol) was added to a solution of 5-bromo-2,4-dichloropyrimidine 4 (100 mmol) in i-PrOH (200 mL) at ambient temperature. The rst batch of the precipitant appeared aer a few minutes of stirring at room temperature. Aer ltration, to the ltrate was added the solution of K 2 CO 3 (300 mmol) in water (200 mL), and the reaction mixture was stirred at room temperature until all of the 5-bromo-2,4-dichloropyrimidine 4 was consumed completely, as shown by TLC monitoring. The resulting second batch of the precipitant was ltered and the lter cake was washed with water and ethyl acetate in sequence. Aer desiccation, the two batches of precipitant were combined to give the 5-bromo-2-chloro-Nphenylpyrimidin-4-amines 6a as a gray solid (16.17 g, 51.4%). 
Synthesis of intermediate 6b
A similar reaction to that described above to prepare 6a was used to obtain 6b as a gray solid (4.9 g, 55% 
Synthesis of intermediate 6c
A similar reaction to that described above to prepare 6a was used to obtain 6c as a white solid (3.5 g, 49% 
Synthesis of intermediate 6d
A similar reaction to that described above to prepare 6a was used to obtain 6d as a light yellow solid (3.8 g, 54% 
Synthesis of intermediate 14a
Briey, to a mixture of 13a (124 g, 2 mol) and triethylamine (12 g, 0.12 mol) in dry DCM (100 mL) was added TsCl (19 g, 0.1 mol) in dry DCM (100 mL) dropwise at 0 C. The solution was stirred at 0 C for 3 h. Then, the reaction was quenched with water. Aer extraction with DCM, the organic phase was washed with water two times. Aer removal of the solvent, the residue was puried by silica gel chromatography to give 14a (12 g, 37.1%) as a colorless oil. 1 H NMR (400 MHz, CDCl 3 ):
3.66-3.71 (m, 2H), 2.45 (s, 3H) (the 1 H NMR data of 14a were identical with those in the literature 27 ).
Synthesis of intermediate 14b
A similar reaction to that described above to prepare 14a was used to obtain 14b as a colorless oil (15 g, 58% 
Synthesis of intermediate 15b
A similar reaction to that described above to prepare 15a was used to obtain 15b as a light yellow solid (10 g, 76% 
Synthesis of intermediate 11a
A similar reaction to that described above to prepare 15a was used to obtain 11a as a light yellow solid (9 g, 74% 
Synthesis of intermediate 12a
A similar reaction to that described above to prepare 15a was used to obtain 12a as a light yellow solid (7.5 g, 68%).
H NMR data of 11a were identical with those in the literature 32 ).
Synthesis of intermediate 16a
A mixture of 15a (4.5 g, 25 mmol) and 7.5% Pd/C (0.45 g) in ethanol (50 mL) was stirred under a H 2 atmosphere for 5 h. The mixture was ltered and the ltrate was concentrated in vacuo. The crude 16a (2.6 g) was used in the next step without further purication since the intermediate 16a was unstable in air. Furthermore, the mole of 16a used in the next step of the reaction was also calculated as the hypothetical mass of pure 16a divided by the relative molecular mass of 16a.
Synthesis of intermediate 16b
A similar reaction to that described above to prepare 16a was used to obtain the crude 16b as a red oil (3.2 g), which was then used in the next step without further purication since the intermediate 16b was unstable in air. Furthermore, the mole of 16b used in the next step of the reaction was also calculated as the hypothetical mass of pure 16b divided by the relative molecular mass of 16b.
Synthesis of intermediate 12a
A similar reaction to that described above to prepare 16a was used to obtain the crude 12a as a red oil (5.4 g), which was then used in the next step without further purication since the intermediate 12a was unstable in air. Furthermore, the mole of 12a used in the next step of the reaction was also calculated as the hypothetical mass of pure 12a divided by the relative molecular mass of 12a.
Synthesis of intermediate 12b
A similar reaction to that described above to prepare 16a was used to obtain the crude 12b as a red oil (4.1 g), which was then used in the next step without further purication since the intermediate 12b was unstable in air. Furthermore, the mole of 12b used in the next step of the reaction was also calculated as the hypothetical mass of pure 12b divided by the relative molecular mass of 12b.
Synthesis of precursor 7
A mixture of the crude compound 3 (0.91 g, 3.0 mmol) and intermediate 6a (0.62 g, 2.0 mmol) in 1,4-dioxane (20 mL) using p-toluenesulfonic acid (0.14 g, 0.8 mmol) as the catalyst was stirred under reux under an inert atmosphere. When intermediate 6a was completely consumed (as monitored by TLC, petroleum ether/ethyl acetate, 3/1, v/v), it was concentrated under reduced pressure. The resulting residue was puried by silica gel column chromatography by eluting with petroleum ether/ethyl acetate (6/1-2/1, v/v) to give the pure compound 7 (60 mg) with the yield of 5.2%. 1 
Synthesis of intermediate 17a
A similar reaction to that described above to prepare 7 was used to obtain the crude 17a (0.57 g), which was then used in the next step without further purication since the intermediate 17a was unstable in air. Furthermore, the mole of the 17a used in the next step of the reaction was also calculated as the hypothetical mass of pure 17a divided by the relative molecular mass of 17a.
Synthesis of intermediate 17b
A similar reaction to that described above to prepare 7 was used to obtain the crude 17b (0.62 g), which was then used in the next step without further purication since the intermediate 17b was unstable in air. Furthermore, the mole of the 17b used in the next step of the reaction was also calculated as the hypothetical mass of pure 17b divided by the relative molecular mass of 17b.
Synthesis of intermediate 17c
A similar reaction to that described above to prepare 7 was used to obtain the crude 17c (0.65 g), which was then used in the next step without further purication since the intermediate 17c was unstable in air. Furthermore, the mole of 17c used in the next step of reaction was also calculated as the hypothetical mass of pure 17c divided by the relative molecular mass of 17c.
Synthesis of intermediate 17d
A similar reaction to that described above to prepare 7 was used to obtain the crude 17d (0.64 g), which was then used in the next step without further purication since the intermediate 17d was unstable in air. Furthermore, the mole of 17d used in the next step of the reaction was also calculated as the hypothetical mass of pure 17d divided by the relative molecular mass of 17d.
Synthesis of intermediate 17e
A similar reaction to that described above to prepare 7 was used to obtain the crude 17e (0.72 g), which was then used in the next step without further purication since the intermediate 17e was unstable in air. Furthermore, the mole of 17e used in the next step of the reaction was also calculated as the hypothetical mass of pure 17e divided by the relative molecular mass of 17e.
Synthesis of intermediate 17f
A similar reaction to that described above to prepare 7 was used to obtain the crude 17f (0.69 g), which was then used in the next step without further purication since the intermediate 17f was unstable in air. Furthermore, the mole of 17f used in the next step of the reaction was also calculated as the hypothetical mass of pure 17f divided by the relative molecular mass of 17f.
Synthesis of precursor 18a
Briey, to a mixture of 17a (570 mg, 1.2 mmol), triethylamine (202 mg, 2 mmol), and 4-dimethylaminepyridine (14 mg, 0.12 mmol) in dry DCM (10 mL) was added TsCl (380 mg, 2 mmol) in dry DCM (10 mL) dropwise at 0 C. The solution was stirred at 0 C for 3 h. Then, the reaction was quenched with water. Aer extraction with DCM, the organic phase was washed with water two times. Aer removal of the solvent, the residue was puried by silica gel chromatography to give 18a (0.30 g, 45%) as a red solid. 1 
Synthesis of precursor 18b
A similar reaction to that described above to prepare 18a was used to obtain 18b as a light yellow solid (0.53 g, 66% 
Synthesis of precursor 18c
A similar reaction to that described above to prepare 18a was used to obtain 18c as a light yellow solid (0.52 g, 60% 
Synthesis of precursor 18d
A similar reaction to that described above to prepare 18a was used to obtain 18d as a light yellow solid (0.52 g, 60% 
Synthesis of precursor 18e
A similar reaction to that described above to prepare 18a was used to obtain 18e as a light yellow solid (0.57 g, 61% 
Synthesis of precursor 18f
A similar reaction to that described above to prepare 18a was used to obtain 18f as a light yellow solid (0.58 g, 66% 
Synthesis of F-19 standard 8a
To a stirred solution of compound 7 (30 mg, 0.05 mmol) in dry THF (4 mL), tetrabutylammonium uoride (0.5 mL, 1 M in THF) was added. The mixture was heated using a digestion highpressure tank at 100 C for 6-7 h. 
Synthesis of F-19 standard 8b
A similar reaction to that described above to prepare 7 was used to obtain 8b (0.46 g, 68%) as a white solid; 1 
Synthesis of F-19 standard 8c
A similar reaction to that described above to prepare 7 was used to obtain 8c (0.69 g, 90%) as a white solid; 1 
Synthesis of F-19 standard 8d
A similar reaction to that described above to prepare 7 was used to obtain 8d (0.94 g, 78%) as a white solid; 1 
Synthesis of F-19 standard 8e
A similar reaction to that described above to prepare 7 was used to obtain 8e (1.20 g, 82%) as a white solid; 
Synthesis of F-19 standard 8f
A similar reaction to that described above to prepare 7 was used to obtain 8f (1.08 g, 75%) as a white solid; 1 
Synthesis of F-19 standard 8g
A similar reaction to that described above to prepare 7 was used to obtain 8g ( 
FAK inhibitory assay
The inhibition tests of the title compounds 8a-8i against FAK were performed using the HTRF® (Homogeneous TimeResolved Fluorescence Methodologies) kinEASE™ TK kit. The concentration of the enzyme used in the assay, as well as the enzymatic reaction time and the ATP concentration were optimized before the compound testing. Here, 0.11 ng mL À1 enzyme was chosen to be used with 13.8 mM ATP to react for 50 min at room temperature. During the enzymatic reaction step, 4 mL of the compound and 2 mL TK substrate-biotin were incubated with 2 mL kinase. 2 mL ATP was added to start the enzymatic reaction. Then, the enzymatic buffer from the HTRF® kinEASE™ TK kit was added, following by the addition of 5 mM MgCl 2 , 1 mM DTT, and 25 nM SEB.
The detection reagents (5 mL Eu
3+
-cryptate labeled TKantibody and 5 mL Steptavidin-XL665) dissolved in the detection buffer (in the presence of EDTA) were mixed and added to the reaction system. The TR-FRET signal was proportional to the phosphorylation level and was detected by a plate reader (BMG FS) aer incubation for 1 h. For each compound, the IC 50 value was determined from a sigmoid dose-response curve using GraphPad Prism (GraphPad Soware, San Diego, CA, USA).
Partition coefficient determination
The determination of the partition coefficients of the radio- according to the following procedure: rst, the same volume of n-octanol and PBS (phosphate buffer saline, 0.05 M, pH 7.4) was mixed, and each phase was presaturated with the opposite phase overnight before use. Then, to a centrifuge tube was added a solution of 18 F-labeled tracer (370 kBq, 10 mCi) in 0.1 mL normal saline, 0.9 mL PBS (presaturated with the opposite phase overnight), and 1.0 mL n-octanol (presaturated with the opposite phase overnight) in sequence. The centrifuge tube was vortexed for 0.5-1.0 min at room temperature, followed by centrifugation for 5 min at 5000 rpm. Aer standing for a while, two samples were transferred from the n-octanol (100 mL) and PBS (100 mL) layers to the counting tubes and were measured in a gamma counter. The partition coefficient was expressed as the logarithm of the ratio of the radioactivity from the n-octanol phase versus the PBS phase. The measurement was done in triplicate and repeated three times.
In vitro stability studies
18 F]-8h, and [ 18 F]-8i (370 kBq, 10 mCi) aer HPLC purication were dissolved in 100 mL of normal saline, and then mixed with 500 mL of normal saline at 37 C for 1 h and 2 h, respectively. About 100 mL of the solution was analyzed by radio-HPLC. The in vitro stability of the 18 F-labeled tracers in mouse plasma was determined using the following procedure: (1) rst, incubate 370 kBq of the HPLC-puried radiotracers in 100 mL of normal saline with 500 mL of murine plasma at 37 C for 1 h and 2 h, respectively; (2) aer centrifuging the plasma proteins at 5000 rpm for 5 min at 4 C, they were precipitated by adding 200 mL of acetonitrile. The supernatant was collected. Approximately 100 mL of the supernatant solution was loaded for the HPLC analysis.
In vivo biodistribution studies in S180-bearing mice An S180 ascites sarcoma mouse was sacriced and the ascites was immediately drawn off from the carcass and made into an S180 sarcoma cell suspension (diluted four times by normal saline). Then, the normal ICR mice were inoculated subcutaneously into the right front ank with the diluted ascites sarcoma cell suspension (100 mL per mouse, containing about 5 Â 10 6 tumor cells by cell count).
The in vivo biodistribution studies could be conducted until the tumors reached a size of 0.5-0.8 cm in diameter (i.e., for about one week). A normal saline solution containing the 18 ]-8i (370 kBq per 100 mL) was injected via the tail vein for each of the S180-tumor-bearing mice. The mice (n ¼ 5 for each time point) were sacriced at 5, 15, 30, 60, and 120 min post-injection. The tissues and organs of interest were anatomized and weighed, and the radioactivity was determined with an automatic g-counter. The percent dose per gram of wet tissue was calculated by a comparison of the tissue counts to suitably diluted aliquots of the injected material. The values were expressed as the mean AE SD (n ¼ 5).
MicroPET imaging
The S180-tumor-bearing mice were injected intravenously with approximately 3.7 MBq of [
18 F]-8a in 300 mL normal saline, anesthetized with 1.5% isourane in air (about 1.5 mL min À1 ), and xed near the center of the microPET scanner (SuperArgus microPET/CT). Static scans (for 30 min and 60 min, 10 min scans for each time point) were obtained on a SuperArgus microPET/CT. Then, the images were reconstructed with the SEDECAL reconstruction soware and the images were exported by MMWKS SUPERARGUS soware.
Results and discussion
Chemistry
The synthetic route used to prepare the pyrimidine derivative 8a is shown in Scheme 1. The starting material 4-nitrophenol 1 was treated with ethane-1,2-diyl bis(4-methylbenzenesulfonate) to give compound 2, which was reduced by Zn to obtain compound 3. Intermediate 6a was obtained by the reaction of 5-bromo-2,4-dichloropyrimidine 4 and 4-methoxyaniline 5a in iPrOH using K 2 CO 3 as a base at room temperature with a yield of 78%. Compound 7 could be prepared by compounds 3 and 6a in 1,4-dioxane at 100 C using p-toluene sulfonic acid as the catalyst, which was further reuxed in THF in the presence of TBAF to provide the target compound 8a.
The synthetic route used to prepare the pyrimidine derivatives 8b-g is shown in Scheme 2. The uorinated products 10a-b were obtained starting from the commercially available materials 9a-b, followed by etherication and hydrogenation to give the key intermediates 12a-b in excellent yields. Another important kind of intermediate 6b-d could be easily prepared by compounds 4 and 5b-d, whereby the former further reacted with compounds 12a-b in 1,4-dioxane at 100 C to provide the target pyrimidine derivatives 8b-g using p-toluene sulfonic acid as the catalyst with 68-90% yields. The synthetic route used to prepare the pyrimidine derivatives 8h and 8i is shown in Scheme 3. The target compounds 8h and 8i with moderate yields were easily synthesized by pyrimidine derivatives 8d and 8g in the mixed solution of ethanol and water at 90 C in the presence of KOH.
All the newly synthesized target pyrimidine derivatives were characterized by 1 H NMR, 13 C NMR, and MS spectra. The spectral data were in accordance with the assigned structures, and all the spectral data are listed in the Experimental section.
FAK inhibitory assay
The prepared compounds 8a-i were evaluated for their in vitro inhibitory activities against FAK using 16-OTS-1 as the positive control. The obtained results are shown in Table 1 .
The results in Table 1 demonstrated that all the target compounds showed superior inhibition against FAK compared to the reference 18c. The most active compound 8i displayed an IC 50 value of 0.060 mM against FAK, which was more than 500-fold lower than 18c (IC 50 ¼ 33.290 mM). When n ¼ 1, compound 8h with a carboxyl group exhibited strong inhibitory activity with an IC 50 value of 0.285 mM, while when n ¼ 2, the carboxylgroup-modied derivative 8i was still the most active one. These outcomes suggested that the carboxyl group was favorable to exert FAK inhibition for this type of pyrimidine derivatives. However, with the change of the carboxyl group into a carboxylic ester moiety, the inhibitory activity is reduced a lot. Comparing compounds with n ¼ 1 (8a-d, 8h) to n ¼ 2 (8e-g, 8i) , the pyrimidine derivatives 8e-g and 8i generally showed stronger activity, which indicated that the length of the aliphatic chain has an important effect on the FAK inhibitory activity.
Radiolabeling
Encouraged by the good inhibitory activity and docking results of most of the newly prepared pyrimidine derivatives against FAK, a radiouorination method for the preparation of (Fig. 4) .
Partition coefficient determination
Selecting potential candidates as FAK targeting tumor imaging agents for further development requires measuring a range of physiochemical properties. 33 The partition coefficient (log P) value governs various biological processes, such as the transportation, distribution, metabolism, and secretion of biomolecules, which is essential to predict their transportation and activity. Therefore, the selected compounds [ stability of these radio-compounds (Fig. 5) .
In vivo biodistribution studies in S180-bearing mice
In vivo biodistribution data in mice bearing the S180 tumor for [ ). Also, a good to moderate uptake was observed in other major organs or tissues, such as the intestine (3.51 AE 0.14 ID% g (Table 3) .
MicroPET imaging
Compound [
18 F]-8a was selected as the microPET imaging agent in the four F-18-labeled pyrimidine derivatives for its good in vivo biodistribution in mice bearing the S180 tumor. In the microPET images, it could be seen that the diffusion of the 
Conclusions
In conclusion, a series of novel pyrimidine derivatives were successfully synthesized and characterized by 1 H NMR, 13 C HNMR, and MS spectra. All the new compounds were evaluated for their activity against FAK, and showed low IC 50 values in comparison with control drugs. Especially for compound 8i, its IC 50 value was 0.060 mM, suggesting its advantage as an FAK inhibitor. To evaluate the potentiality of these compounds as PET imaging agents in cancer detection, compounds 8a, 8c, 8h, and 8i were successively labeled with ]-8a with a 4-methoxyl group at the benzene ring exhibited good in vivo biodistribution data in mice bearing the S180 tumor, which promoted its further microPET imaging study. MicroPET image of [ 18 F]-8a administered into S180-tumor-bearing mice acquired at 60 min post-injection illustrated that the uptake in the S180 tumor was obvious. These results suggested that compound [ 18 F]-8a might be a promising PET tracer candidate for tumor detection. On the other hand, on-going efforts to optimize the structure of [ 18 F]-8a aimed at enhancing the tumor-to-nontarget ratios in vivo are under way. Furthermore, in order to enhance the uptake of the F-18-labeled tracer in tumor and its target/ nontarget ratios, the interaction between the corresponding F-19 standards and the FAK should be further increased and the log P should be further properly lowered in future designs.
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